Varicella zoster disease of the central nervous system: Epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine

Journal of Infectious Diseases

Volumn 203, Issue 3, 2011, Pages 316-323

  Pahud, Barbara A ^a,c   Glaser, Carol A ^b   Dekker, Cornelia L ^c   Arvin, Ann M ^c   Schmid, D Scott ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; FOSCARNET;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ADOLESCENT; ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CHILD; CLADISTICS; CLINICAL FEATURE; DESCRIPTIVE RESEARCH; FEMALE; GENOTYPE; HERPES ZOSTER; HERPES ZOSTER ENCEPHALITIS; HERPES ZOSTER OPHTHALMICUS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENINGITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS STRAIN; WILD TYPE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENCEPHALITIS, VARICELLA ZOSTER; FEMALE; HUMANS; INFANT; MALE; MENINGITIS, VIRAL; MIDDLE AGED; TIME FACTORS; YOUNG ADULT;

EID: 79751517331     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq066     Document Type: Article

References (35)

1. Centers for Disease Control Prevention. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1-36.
2. Lopez AS, Kolasa MS, Seward JF. Status of school entry requirements for varicella vaccination and vaccination coverage 11 years after implementation of the varicella vaccination program. J Infect Dis 2008; 197(suppl 2);S76-81.
3. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-40.
4. Koskiniemi M, Rantalaiho T, Piiparinen H, et al. Infections of the central nervous system of suspected viral origin: A collaborative study from Finland. J Neurovirol 2001; 7:400-8. (Pubitemid 33040428)
5. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
6. Nagel MA, Gilden DH. The protean neurologic manifestations of varicella-zoster virus infection. Cleve Clin J Med 2007; 74:489-94, 496, 498-9, 502-4.
7. Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: Experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis 2008; 197(suppl 2);S170-7.
8. Iyer S, Mittal MK, Hodinka RL. Herpes zoster and meningitis resulting from reactivation of varicella vaccine virus in an immunocompetent child. Ann Emerg Med 2009; 53:792-5.
9. Levin MJ, DeBiasi RL, Bostik V, Schmid DS. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J Infect Dis 2008; 198:1444-7.
10. Levin MJ, Dahl KM, Weinberg A, Giller R, Patel A, Krause PR. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child. J Infect Dis 2003; 188:954-9. (Pubitemid 37268243)
11. Chouliaras G, Spoulou V, Quinlivan M, Breuer J, Theodoridou M. Vaccine-associated herpes zoster ophthalmicus [correction of opthalmicus] and encephalitis in an immunocompetent child. Pediatrics 2009; 125:e969-72.
12. Galea SA, Sweet A, Beninger P, et al. The safety profile of varicella vaccine: A 10-year review. J Infect Dis 2008; 197(suppl 2); S165-9.
13. Goulleret N, Mauvisseau E, Essevaz-Roulet M, Quinlivan M, Breuer J. Safety profile of live varicella virus vaccine (Oka/Merck): Five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP). Vaccine 2010; 28:5878-82.
14. Glaser CA, Honarmand S, Anderson LJ, et al. Beyond viruses: Clinical profiles and etiologies associated with encephalitis. Clin Infect Dis 2006; 43:1565-77. (Pubitemid 44901899)
15. Loparev VN, McCaustland K, Holloway BP, Krause PR, Takayama M, Schmid DS. Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J Clin Microbiol 2000; 38:4315-9. (Pubitemid 32244512)
16. Lopez AS, Burnett-Hartman A, Nambiar R, et al. Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004. J Infect Dis 2008; 197:646-53. (Pubitemid 351364461)
17. Loparev VN, Gonzalez A, Deleon-Carnes M, et al. Global identification of three major genotypes of varicella-zoster virus: Longitudinal clustering strategies for genotyping. J Virol 2004; 78:8349-58. (Pubitemid 38944319)
18. Loparev VN, Rubtcova EN, Bostik V, et al. Identification of five major and two minor genotypes of varicella-zoster virus strains: A practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand. J Virol 2007; 81:12758-65. (Pubitemid 350156913)
19. Breuer J, Grose C, Norberg P, Tipples G, Schmid DS. A proposal for a common nomenclature for viral clades that form the species varicellazoster virus: Summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. J Gen Virol 2010; 91:821-8.
20. Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5771-92. (Pubitemid 47049772)
21. Tapiainen T, Prevots R, Izurieta HS, et al. Aseptic meningitis: Case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine 2007; 25:5793-802. (Pubitemid 47043212)
22. Miller AE. Selective decline in cellular immune response to varicellazoster in the elderly. Neurology 1980; 30:582-7. (Pubitemid 10073082)
23. Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982; 142:291-3. (Pubitemid 12180803)
24. Wang D, Bortolussi R. Acute viral infection of the central nervous system in children: An 8-year review. Can Med Assoc J 1981; 125:585-9. (Pubitemid 11031529)
25. Nicolosi A, Hauser WA, Beghi E, Kurland LT. Epidemiology of central nervous system infections in Olmsted County, Minnesota, 1950-1981. J Infect Dis 1986; 154:399-408.
26. Cizman M, Jazbec J. Etiology of acute encephalitis in childhood in Slovenia. Pediatr Infect Dis J 1993; 12:903-8. (Pubitemid 23325166)
27. Koskiniemi M, Korppi M, Mustonen K, et al. Epidemiology of encephalitis in children. A prospective multicentre study. Eur J Pediatr 1997; 156:541-5. (Pubitemid 27289853)
28. Guess HA, Broughton DD, Melton LJ III, and Kurland LT. Population-based studies of varicella complications. Pediatrics 1986; 78:723-7. (Pubitemid 16007074)
29. Huppatz C, Durrheim DN, Levi C, et al. Etiology of encephalitis in Australia, 1990-2007. Emerg Infect Dis 2009; 15:1359-65.
30. Mailles A, Stahl JP. Infectious encephalitis in france in 2007: A national prospective study. Clin Infect Dis 2009; 49:1838-47.
31. Tien RD, Felsberg GJ, Osumi AK. Herpesvirus infections of the CNS: MR findings. AJR Am J Roentgenol 1993; 161:167-76. (Pubitemid 23208771)
32. Loparev V, Martro E, Rubtcova E, et al. Toward universal varicellazoster virus (VZV) genotyping: Diversity of VZV strains from France and Spain. J Clin Microbiol 2007; 45:559-63.
33. Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN. Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 2007; 14:1057-61. (Pubitemid 47518070)
34. LaRussa P, Lungu O, Hardy I, Gershon A, Steinberg SP, Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992; 66:1016-20.
35. Jean-Philippe P, Freedman A, Chang MW, et al. Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics 2007; 120:e1345-9.